H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
15%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Get your full text copy in PDF

Fas and Fas ligand as prognostic factors in human breast carcinoma

Marek Bebenek, Danuta Duś, Joanna Koźlak

Med Sci Monit 2006; 12(11): CR457-461

ID: 462574


Background: Several studies on breast cancer patients indicate that Fas/FasL status may have a signifi cant impact on patient survival, but their conclusions are still controversial. The aim of this study was to determine the prognostic value of Fas and Fas ligand (FasL) expressions in the early stages of breast
cancer.
Material/Methods: One hundred and eight patients aged 35–77 years (median: 58), mostly with stage I or II tumors, were analyzed.
Results: Signifi cant associations were noted between Fas expression and lymph node involvement (p

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree